IP & New Chemical Entity
Our current patent portfolio contains about 20 patent families for complex APIs (polymorphs, and routes of synthesis) and formulations.
New Chemical Entity
Our U.S. patent application with respect to our pentapolymer NCE was allowed in July 2015. We have conducted preliminary pre-clinical studies of this novel pentapolymer.
We are developing a new chemical entity (NCE); a novel pentapolymer for treating autoimmune diseases such as MS.
patent families of
complex APIs &